Recent clinical research from BGI Genomics and Zhongshan Hospital, Fudan University, highlights the effectiveness of ...
Ted Karkus, CEO and Chairman of the Board of Directors, will be presenting at 1PM ET on October 30 th. One-on-one investor meetings will be held throughout the day. Interested investors can register ...
CHESAPEAKE, Va. — A local youth baseball team honored one of its player’s fathers at a tournament Saturday. Virginia Beach ...
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics and precision <a target=_blank href= ...
GARDEN CITY, NY, Oct. 17, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and diagnostics company, today announced ...
FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...
Stand Up To Cancer ® (SU2C) today announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, ...
Spatial dynamics of CD39 + CD8 + exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer Immune checkpoint blockade (ICB) benefits esophageal ...
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...
While the nearly 33% proposed tax hike will hit every property owner in Lackawanna County for many low-income taxpayers, it could be especially difficult.
Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) shares saw strong trading volume on Tuesday after BTIG Research raised their price target on the stock from $35.00 to $40.00. BTIG Research ...
Castle Biosciences (NASDAQ:CSTL – Get Free Report) had its price target hoisted by equities researchers at BTIG Research from $35.00 to $40.00 in a report released on Monday, Benzinga reports. The ...